GlassScriptPhysician profile
Rhea Randhawa
NPI 1780305409
$2,496.59
in general payments reported to CMS, 2019-2025
31 companies · $2,436 in 2025
The $2,436 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $60.48 · 2025: $2,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,391 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,390.82 |
| Education | $105.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $422.73 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $338.70 | 2025 | |
| Novo Nordisk INC | $218.99 | 2023-2025 | Ozempic, Wegovy |
| Abbvie INC. | $156.90 | 2025 | |
| Phathom Pharmaceuticals, INC. | $133.95 | 2025 | Voquezna |
| Medtronic, INC. | $129.59 | 2025 | Minimed 780g |
| Opko Pharmaceuticals, LLC | $105.77 | 2025 | Rayaldee |
| Lilly USA, LLC | $87.79 | 2025 | Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $86.35 | 2025 | Trelegy Ellipta, Arexvy |
| Ardelyx, INC. | $77.65 | 2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $76.61 | 2025 | Jynarque, Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.58 | 2025 | Xifaxan |
| Vanda Pharmaceuticals INC. | $72.56 | 2025 | Fanapt, Hetlioz |
| Pfizer INC. | $58.25 | 2025 | |
| Dexcom, INC. | $53.66 | 2025 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $49.87 | 2025 | Auvelity |
| Exact Sciences Corporation | $47.84 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.18 | 2025 | Caplyta |
| Argenx US, INC. | $34.56 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Corcept Therapeutics | $31.06 | 2025 | Korlym |
| Electromed, INC. | $22.86 | 2025 | Smartvest |
| Viatris Specialty LLC | $22.01 | 2025 | Yupelri |
| Csl Behring | $20.86 | 2025 | Andembry |
| Merck Sharp & Dohme LLC | $20.13 | 2025 | Verquvo |
| Aimmune Therapeutics, INC. | $20.00 | 2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.92 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $16.95 | 2025 | |
| Verona Pharma, INC. | $16.49 | 2025 | Ohtuvayre |
| Amgen INC. | $15.29 | 2023 | Repatha, Otezla |
| Astellas Pharma US INC | $14.60 | 2023 | Veozah |
| Insulet Corporation | $13.89 | 2025 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhea Randhawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.